Top 10 Pharma Companies (excl. Generics) in India in 2021 by Revenues

Glenmark Pharmaceuticals Ltd, Biocon Ltd, Ajanta Pharma Ltd, Panacea Biotec Ltd, and Sun Pharma Advanced Research Company Ltd are the top 5 pharmaceutical companies (excl. Generics) in India in 2021 by revenue. Cumulatively, the top 10 pharmaceutical companies (excl. Generics) in India generated revenue of $2,945 million, with average revenue growth of 54.41%, the highest revenue was generated by Glenmark Pharmaceuticals Ltd ($1,481 million), followed by Biocon Ltd ($962 million) and Ajanta Pharma Ltd ($391 million), while Sun Pharma Advanced Research Company Ltd ($34 million) stood the lowest. The highest revenue growth was registered by Sun Pharma Advanced Research Company Ltd (229.31%), followed by Panacea Biotec Ltd (14.84%), while Glenmark Pharmaceuticals Ltd registered the lowest revenue growth of 2.85%. The top 10 pharma companies employed a total of 26,885 people in 2021. India-based Glenmark Pharmaceuticals Ltd Inc is one of the top Companies (excl. Generics) in India in 2021 by Revenue (FY 2021). The company focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. Its formulation business spans various geographies, including India, the US, Europe, Latin America, and the rest of the world. The company provides contract development and manufacturing operations services to various multinational and specialty pharmaceutical companies. It generated revenue of $1,481 million with average revenue growth of 2.9% and employed 11,550 people. India-based Biocon Ltd is one of the top Companies (excl. Generics) in India in 2021 by Revenue (FY 2021). It is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes, and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics, and biosimilars including monoclonal antibodies (MAbs), RH-Insulin and insulin analogs. The company reported revenue of $962 million with average revenue growth of 13.4%. The company classified its business into four segments: Generics, Biosimilars, Novel Biologics, and Research Services, also generates revenue through other income and employed 3,203 people.